Abstract: Background: Dietary polyphenols, including flavonoids, have been the focus of major recent attentions due to their wide content in a variety of foods commonly consumed and the findings from numerous studies showing evidence of an association with positive outcomes on human health. Methods: A systematic search using electronic databases PubMed and EMBASE was performed to retrieve English language studies published from the earliest indexing year of each database to April 2019, reporting on the association between dietary flavonoids intake and hypertension. Results: The search strategy resulted in the final selection of 20 studies including 15 cross-sectional investigations and 7 prospective cohorts (1 study reported on 3 prospective cohorts). 5 prospective cohorts, comprising 200,256 individuals and 45,732 cases of hypertension were included in the quantitative analysis. Analysis by extreme quantiles of intake of flavonoid showed a non-significant association with decreased risk of hypertension (RR (risk ratio): 0.96, 95% CI (confidence interval): 0.89, 1.03). Taking into consideration individual flavonoid subclasses, dietary anthocyanins intake was associated with 8% reduction in risk of hypertension, when comparing highest vs. lowest exposure (RR: 0.92, 95% CI 0.88, 0.97). Conclusions: Further studies are needed to strengthen the retrieved association between anthocyanins consumption and decreased risk of hypertension and clarify whether total flavonoids or rather individual subclasses may exert beneficial effects on blood pressure.

Keywords: flavonoid; anthocyanin; flavones; hypertension; blood pressure; meta-analysis; cohort

1. Introduction

The reduction in cardiovascular risk and metabolic disorders associated with healthy diets have been hypothesized to be mediated, among several mechanisms, by their content in
bioactive phytochemicals possibly endorsed of antioxidant and anti-inflammatory properties [1]. Dietary polyphenols have been recently put under the spotlight due to their wide content in a variety of commonly consumed foods, and to the findings from numerous studies showing significant evidence of their association with positive outcomes in the framework of human health [2,3]. Among the most studied, flavonoids represent the most heterogeneous class in terms of both chemical structure and bioactivity [4]. This class of polyphenols is characterized by C6–C3–C6 ring structure substituted with varying numbers of hydroxyl groups. The bioavailability, metabolism, and biological activity of flavonoids depends on their configuration, total number of hydroxyl groups, substitution or conjugation of functional groups, and degree of polymerization [5]. The flavonoid class is composed of several sub-classes, including anthocyanins, isoflavones, flavones, flavonols, flavanones, flvan-3-ols, and the related oligomeric proanthocyanidins. Each of these sub-classes is contained in a pattern of different foods, mostly fruits and some vegetables, but also in teas, cocoa, and some alcoholic beverages, which have been shown to exert beneficial effects toward human health [6–12]. Despite the now recognized inter- and intra-individual differences in absorption and metabolism, dietary flavonoids have been considered as potentially responsible, at least in part, for the beneficial effects associated to plant-based dietary patterns and of many of the benefits attributed to plant-derived beverages, such as tea and coffee [13,14]. Moreover, the dietary intake of polyphenols has been linked to higher adherence to a healthy dietary pattern [15], namely the Mediterranean diet, that has been adopted worldwide [16]. Importantly, different studies showed the association between higher adherence to Mediterranean pattern, a rich source of flavonoids, and lower prevalence of metabolic features, such as dyslipidemia [17], obesity [18–22], and hypertension [23,24].

There is a growing interest in the association between dietary flavonoid intake and cardio-metabolic risk factors. Results from laboratory and clinical investigations have pointed out the potential benefits of some classes of flavonoids in regulating blood pressure and endothelial function [25–28]. Studies conducted in the context of the PREDIMED (PREvencion con DIeta MEDiterranea) trial provided mechanistic evidence of association between total polyphenol excretion, blood pressure levels [29], and plasma nitric oxide production, which is a regulating factor of endothelial function [30]. However, no specific data on flavonoids was provided. Taking into account the documented heterogeneity in structural characteristics, bioavailability, absorption, and metabolism, it is of interest to summarize the existing evidence and evaluate which group of compounds provide the most robust and promising health effect. Thus, the aim of this study was to perform a meta-analysis of prospective cohort studies investigating the effects of the intake of total and individual subclasses of dietary flavonoids on the risk of hypertension.

2. Materials and Methods

2.1. Study Selection

A systematic search on electronic databases PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) and EMBASE (http://www.embase.com/) was performed to retrieve English language studies published from beginning to April 2019 using the following search terms: (i) flavonoids, flavonols, flavones, anthocyanidins, flavanones, flvan-3-ols, catechins, isoflavones, proanthocyanidins, quercetin, myricetin, kaempferol; (ii) lignans, phytoestrogens; (iii) hypertension, blood pressure, cardiovascular, metabolic; and (iv) cohort, prospective, cross-sectional, longitudinal. Inclusion criteria were the following: (i) having a prospective design; (ii) evaluating the association between dietary flavonoids/lignans and/or their classes intake and risk of hypertension; (iii) assessed and reported hazard ratios (HRs) and the corresponding 95% CI (confidence interval) for hypertension (or sufficient data to compute them). No specific exclusion criteria were applied besides language restrictions. Reference lists the studies retrieved were examined to find any additional study potentially unidentified. If more than one article referred to the same cohort, only the study that included the entire cohort or
with the longest follow-up was included. The selection process was independently performed by two authors (G.G. and J.G.) and retrieved articles were examined.

2.2. Data Extraction and Study Quality

Data were extracted from each eligible study by using a standardized extraction form. The following information was included: (1) first author name; (2) year of publication; (3) cohort name; (4) country; (5) number of participants (analyzed cohort); (6) sex of participants; (7) age range of the study population at baseline; (8) dietary food source; (9) sources used to calculate polyphenol intake; (10) follow-up period; (11) number of cases; (12) distributions of cases and person-years, HRs, and 95% CIs for all categories of exposure; (13) covariates used in adjustments. This process was independently performed by two authors (G.G. and J.G.) and discrepancies were discussed and resolved by consensus.

The quality of each study was assessed using the Newcastle-Ottawa Quality Assessment Scale [31]. The scale consists of three variables evaluating the quality of studies, including: selection (4 points), comparability (2 points), and outcome (3 points) for a total score of 9 points (9 representing the highest quality).

2.3. Statistical Analysis

Outcomes evaluated in the analyses included occurrence of hypertension. The analyses were performed for total flavonoid intake as well as for individual classes. HRs with 95% CI for all categories of exposure were extracted for the analysis. Random-effects models were used in order to estimate relative risks (RRs) with 95% CIs for the highest versus the lowest category of exposure. The risk estimate from the most adjusted models were used in the analysis. Heterogeneity was calculated using the Q test and $I^2$ statistic. The level of significance for the Q test was expressed as $p < 0.10$. The $I^2$ statistic represented the amount of total variation that could be attributed to heterogeneity. $I^2$ values ≤25%, 25–50%, 50–75%, and >75% indicated no, small, moderate, and significant heterogeneity, respectively. A sensitivity analysis by exclusion of one study at the time was performed in order to assess the stability of results and potential sources of heterogeneity. Additional sensitivity analyses were performed to test for potential source of heterogeneity by grouping studies according to sex, geographical area, sample size, length of follow-up, and adjustment for potential confounding factors. Publication bias was evaluated by a visual investigation of funnel plots for potential asymmetry.

3. Results

3.1. Study Characteristics

The process of identification and study selection is summarized in Figure 1. Among the initial 469 articles screened on the basis of title, 27 articles were screened by reading full-texts. Seven studies were excluded after a full-text examination for the following reasons: two studies reported insufficient statistics, four studies reported markers of polyphenol consumption, one study provided the results only for metabolic syndrome and not hypertension or blood pressure. This search strategy resulted in the final selection of 20 studies, including 15 cross-sectional investigations and 7 prospective cohorts (1 study reported on 3 prospective cohorts). Five prospective cohorts, comprising 200,256 individuals and 45,732 cases of hypertension, were included in the quantitative analysis.
were conducted in the US, including the Health Professionals’ Follow-up Study (HPFS), the Nurses’
Among studies on flavonoid intake, TOT also reported individual subclasses, such as flavonols,
(40–70 years’ old. Study quality was consistently high (Table 1). A total of six studies
Investigation into Cancer and Nutrition (EPIC); and two conducted in Asia included Japan Public
COHORT (HAPIEE) study [33] and the E3N, which is the French component of the European Prospective
in Adolescence (HELENA) study, the Korean National Health and Nutrition Examination Survey
in Adolescence (HELENA) study, the Korean National Health and Nutrition Examination Survey
(such as age, sex (when not analyzed separately), BMI, education, physical activity, and smoking status; however, not all
may have significantly influenced the endpoint outcome (hypertension), such as age, sex (when
consumption, and risk of hypertension. Growth and Longevity (TOSCA.IT) and TwinUK registry study, the Tehran Lipid
Education, Aging, and Lifestyle (MEAL) study, the WOBASZ study, the Health Survey of Sao Paulo (ISA-Capital Study),
the Framingham Offspring Study, the TOSCA.IT study, the TwinUK registry study, the Tehran Lipid
and Lifestyle (MEAL) study, the WOBASZ study, the Health Survey of Sao Paulo (ISA-Capital Study),
and Lifestyle (MEAL) study, the WOBASZ study, the Health Survey of Sao Paulo (ISA-Capital Study),
and Psychosocial factors in Eastern Europe (HAPIEE) and the CARDIA study. Among prospective studies, three cohorts were
conducted in the US, including the Health Professionals’ Follow-up Study (HPFS), the Nurses’ Health Study I (NHS I) and
the NHS II [32]; the two cohorts conducted in Europe included the Health, the Alcohol and Psychosocial factors in Eastern Europe
(HAPIEE) study [33] and the E3N, which is the French component of the European Prospective Investigation into Cancer and Nutrition (EPIC); and
two conducted in Asia included Japan Public Health Center–Based Cohort II (JPHC-II) and Multi-Rural Communities Cohort (MRCohort) [34]. The cohort size varied between 301 and 87,242 individuals. Most of the studies included adult individuals ranging 40–70 years’ old. Study quality was consistently high (Table 1). A total of six studies investigated exposure to total polyphenols including various classes, six studies focused on flavonoids, two on phenolic acids, and eight studies on phytoestrogens. Among studies on flavonoid intake, TOT also reported individual subclasses, such as flavonols, flavones, flavanones, flavan-3-ols, anthocyanins, and oligomers. All studies included covariates that may have significantly influenced the endpoint outcome (hypertension), such as age, sex (when not analyzed separately), BMI, education, physical activity, and smoking status; however, not all studies adjusted for key dietary factors that might influence risk of hypertension, such as sodium and potassium intake (Table 1).

Estimation of dietary polyphenol intake was performed by using more frequently the Phenol-Explorer database, the US Department of Agriculture (USDA) Flavonoid Content of Food

Figure 1. Process selection of relevant studies reporting on the association between dietary flavonoid intake and risk of hypertension.

Description of main characteristics of the included studies are presented in Table 1. Cross-sectional studies included several cohorts, including the following: the Mediterranean healthy Eating, Aging, and Lifestyle (MEAL) study, the WOBASZ study, the Health Survey of Sao Paulo (ISA-Capital Study), the Framingham Offspring Study, the TOSCA.IT study, the TwinUK registry study, the Tehran Lipid and Glucose Study (TLGS), the Prospect-EPIC cohort, the Healthy Lifestyle in Europe by Nutrition in Adolescence (HELENA) study, the Korean National Health and Nutrition Examination Survey (KNHANES), the Prevención con Dieta Mediterránea (PREDIMED) study, the Alcohol and Psychosocial factors in Eastern Europe (HAPIEE) and the CARDIA study. Among prospective studies, three cohorts were conducted in the US, including the Health Professionals’ Follow-up Study (HPFS), the Nurses’ Health Study I (NHS I) and the NHS II [32]; the two cohorts conducted in Europe included the Health, the Alcohol and Psychosocial factors in Eastern Europe (HAPIEE) study [33] and the E3N, which is the French component of the European Prospective Investigation into Cancer and Nutrition (EPIC); and two conducted in Asia included Japan Public Health Center–Based Cohort II (JPHC-II) and Multi-Rural Communities Cohort (MRCohort) [34]. The cohort size varied between 301 and 87,242 individuals. Most of the studies included adult individuals ranging 40–70 years’ old. Study quality was consistently high (Table 1). A total of six studies investigated exposure to total polyphenols including various classes, six studies focused on flavonoids, two on phenolic acids, and eight studies on phytoestrogens. Among studies on flavonoid intake, TOT also reported individual subclasses, such as flavonols, flavones, flavanones, flavan-3-ols, anthocyanins, and oligomers. All studies included covariates that may have significantly influenced the endpoint outcome (hypertension), such as age, sex (when not analyzed separately), BMI, education, physical activity, and smoking status; however, not all studies adjusted for key dietary factors that might influence risk of hypertension, such as sodium and potassium intake (Table 1).

Estimation of dietary polyphenol intake was performed by using more frequently the Phenol-Explorer database, the US Department of Agriculture (USDA) Flavonoid Content of Food

Figure 1. Process selection of relevant studies reporting on the association between dietary flavonoid intake and risk of hypertension.

Table 1. Description of main characteristics of the included studies.
Database, and the European Food Information Resource (EuroFIR) Bioactive Substances in Food Information System (eBASIS) database, despite individual studies also used other databases (Table 1). The main differences across studies regarded the representativeness of the exposed cohort, as the US cohorts included individuals with demographical (i.e., post-menopausal women or adolescents), health (i.e., diabetic individuals), and social (i.e., health care workers) characteristics different from general population.

3.2. Total Polyphenols, Flavonoids, Phenolic Acids, and Blood Pressure/Hypertension

Total polyphenol or individual classes intake was evaluated in five studies. All studies had a cross-sectional design. In a study investigating major cardiovascular risk factors in a population of 2573 individuals (aged 50 to 75 years) with type 2 diabetes (the TOSCA.IT study), there was a significant lower mean systolic and diastolic blood pressure in the highest tertile of total polyphenol, flavonoids, and phenolic acids intake compared to the lowest one [11]. In another study conducted on 1898 women, aged from 18 to 75 y from the TwinsUK registry, intakes of total flavonoids and their subclasses (flavanones, anthocyanins, flavan-3-ols, polymers, flavonols, and flavones) were estimated from validated FFQs using an updated and extended USDA database; among the various groups of compounds tested, only anthocyanins were linearly associated with systolic blood pressure [35]. In a pan-european study conducted on adolescents participating to the HELENA study (n = 657) in which polyphenol intake was assessed through two 24-h recalls and evaluated using the Phenol-Explorer database, total polyphenol intake was not related with blood pressure, but sub-analyses on polyphenol classes revealed that flavonoid intake was non-significantly associated with higher diastolic blood pressure [36]. Finally, a study conducted on 8821 Polish men and women (the HAPIEE study) using a FFQ and estimation of total/individual polyphenols through the Phenol-Explorer database showed a linear inverse association between total polyphenol intake and high blood pressure (>130/85 mmHg), while, among individual classes, a significant inverse association was found with phenolic acid intake [37].

Among studies conducted outside Europe, an investigation conducted on 2618 Iranian adults, aged 19 to 84 years, showed that total polyphenol intake (assessed by a FFQ and calculated through the Phenol-Explorer database) was not related with hypertension, while among various individual classes, flavonoid intake was linearly inversely associated with systolic and diastolic blood pressure [38]. A study conducted in the context of the Health Survey of Sao Paulo (ISA-Capital) among 550 adults and older adults in Sao Paulo, Brazil assessed total polyphenol intake through two 24-h dietary recalls reporting an inverse association between the highest tertiles of tyrosols, alkylphenols, lignans, as well as stilbenes and occurrence of hypertension; however, total polyphenol intake, and phenolic acids intake was significantly associated only in the middle tertile with hypertension, while association between flavonoids intake and hypertension was not significant [39].
Table 1. Characteristics of prospective cohort studies investigating the relation between dietary polyphenol intake and blood pressure/hypertension

| Author, Year | Cohort Name, Country | Study Design | Follow-Up (Years of Study) | Total Population (Analyzed Sample) | Cases (Hypertension/High Blood Pressure) | Sex | Age | Dietary Assessment | Polyphenol Estimation | Polyphenol Classes | Hypertension Assessment | Adjustments |
|--------------|----------------------|-------------|---------------------------|-----------------------------------|----------------------------------------|-----|-----|-------------------|----------------------|------------------|---------------------|-------------|
| Vitale, 2006 [11] | TOSCA IT, Italy | Cross-sectional | NA | 2573 | NR | MF | 50–75 y (range) | 248-item FFQ | USDA and Phenol-Explorer database | Flavonoids, phenolic acids | Blood pressure measured during clinical visit | Gender, age, BMI, waist and hip circumferences, smoke, alcohol intake, dietary lipids, SFA, MUFA, PUFA, added sugars, and fiber. Age and smoking, BMI, PA, alcohol consumption, family history of hypertension, aspirin use, multivitamin use, and intakes of sodium, magnesium, potassium, fiber, whole grain, folate, and caffeine. |
| Cassidy, 2011 [32] | NHS I, USA | Prospective | 14 y (1990–2004) | 46,672 | 17,616 | F | 30–55 y (range) | FFQ | USDA and EuroFIR database, published literature | Flavonoids (and subclasses) | Self-reported | Age and smoking, BMI, PA, alcohol consumption, family history of hypertension, aspirin use, multivitamin use, and intakes of sodium, magnesium, potassium, fiber, whole grain, folate, and caffeine. |
| Cassidy, 2011 [32] | NHS II, USA | Prospective | 14 y (1991–2005) | 87,242 | 11,402 | F | 25–42 y (range) | FFQ | USDA and EuroFIR database, published literature | Flavonoids (and subclasses) | Self-reported | Age and smoking, BMI, PA, alcohol consumption, family history of hypertension, aspirin use, multivitamin use, and intakes of sodium, magnesium, potassium, fiber, whole grain, folate, and caffeine. |
| Cassidy, 2011 [32] | HPFS, USA | Prospective | 14 y (1990–2004) | 23,043 | 5,629 | M | 40–75 y (range) | FFQ | USDA and EuroFIR database, published literature | Flavonoids (and subclasses) | Self-reported | Age and smoking, BMI, PA, alcohol consumption, family history of hypertension, aspirin use, multivitamin use, and intakes of sodium, magnesium, potassium, fiber, whole grain, folate, and caffeine. |
| Grosso, 2017 [33] | HAPIEE, Poland | Prospective | 4 y (2002–2005) | 2725 | 1735 | MF | 45–69 y (range) | 148-item FFQ | Phenol-Explorer database | Total polyphenols, flavonoids (and subclasses), phenolic acids (and subclasses), stilbenes, lignans, others | Blood pressure measured during clinical visit | Age, total energy intake, BMI, PA, educational status, smoking status, alcohol consumption sodium, potassium and fiber intake, menopausal status (women only). |
Table 1. Cont.

| Author, Year | Cohort Name, Country | Study Design | Follow-Up (Years of Study) | Total Population (Analyzed Sample) | Cases Hypertension (High Blood Pressure) | Sex | Age | Dietary Assessment | Polyphenol Estimation | Polyphenol Classes | Hypertension Assessment | Adjustments |
|--------------|----------------------|--------------|-----------------------------|-----------------------------------|----------------------------------------|-----|-----|-------------------|----------------------|---------------------|---------------------|-------------|
| Lajous, 2016 [34] | E3N, France | Prospective | 14 y (1993–2008) | 40,574 | 9350 | F | 45–58 y (range) | 208-item FFQ | Phenol-Explorer database | Flavonoids (and subclasses) | Self-reported |
| Jennings, 2012 [35] | TwinsUK, UK | Cross-sectional | NA | 1898 | NR | F | 18–75 y (range) | 131-item FFQ | USDA and Phenol-Explorer database | Flavonoids (and subclasses) | Blood pressure measured during clinical visit |
| Wisuwuwandani, 2019 [36] | HELENA, multicenter Europe | Cross-sectional | NA | 657 | NR | MF | 12.5–17.5 y (range) | 24 h dietary recall | Phenol-Explorer database | Total polyphenols | Blood pressure measured during clinical visit |
| Grosso, 2017 [37] | HAPFEE, Poland | Cross-sectional | NA | 8821 | 5,341 | MF | 45–69 y (range) | 148-item FFQ | Phenol-Explorer database | Total polyphenols, flavonoids, phenolic acids, stilbenes, lignans, others | Blood pressure measured during clinical visit |
| Sohrab, 2013 [38] | TLGS, Iran | Cross-sectional | NA | 2618 | NR | MF | 19–84 y (range) | 168-item FFQ | USDA and Phenol-Explorer database | Total polyphenols, flavonoids, phenolic acids, stilbenes, lignans | Blood pressure measured during clinical visit |

Education, family history of hypertension, diabetes, hypercholesterolemia, BMI, smoking, PA metabolic equivalents per week, hormone therapy, alcohol, processed meat, caffeine, magnesium, potassium, and omega-3.

Age, current smoking, physical activity, BMI, use of hormone replacement therapy, use of blood pressure or statin medication, use of vitamin supplements, use of oral contraceptives, menopausal status, family history of heart disease or hypertension, and intakes of energy, alcohol, SFAs, MUFAs, PUFAs, fiber, and sodium.

Age, sex, European region, education of mother, education of father, puberty status, BMI, monosaccharides and disaccharides, polysaccharides, fibre, monounsaturated fatty acids, saturated fatty acids, cholesterol, protein, vitamin C, and energy intake.
### Table 1. Cont.

| Author, Year | Cohort Name, Country | Study Design | Follow-Up (Years of Study) | Total Population (Analyzed Sample) | Cases (Hypertension/High Blood Pressure) | Sex | Age | Dietary Assessment | Polyphenol Estimation | Polyphenol Classes | Hypertension Assessment | Adjustments |
|--------------|----------------------|--------------|-----------------------------|-----------------------------------|----------------------------------------|-----|-----|-------------------|----------------------|-------------------|------------------------|-------------|
| Miranda, 2016 [39] | ISA-Capital Study, Brazil | Cross-sectional | NA | 550 | 267 | MF | ≥12 y | 24 h dietary recalls | Phenol-Explorer database | Total polyphenols, flavonoids, phenolic acids, stilbenes, lignans, others (and subclasses) | Blood pressure measured during home visit | Age, sex, race, educational level, BMI, smoking, physical activity, intake of sodium, fiber, saturated fat, alcohol, total energy intake, misreporting, and other polyphenol components. |
| Miranda, 2017 [40] | ISA-Capital Study, Brazil | Cross-sectional | NA | 557 | NR | MF | 45.1 y (mean) | 24 h dietary recalls | Phenol-Explorer database | Coffee polyphenols (phenolic acids and others) | Blood pressure measured during home visit | Age, sex, race, BMI, smoking, alcohol, physical activity, household per capita income, intake of caffeine, added sugars, total energy intake, and saturated fat, other polyphenol intake. Age, energy intake, BMI, smoking status, alcohol consumption, physical activity level, educational level, occupational level, menopausal status, fiber, sodium, potassium, magnesium, and calcium intake, adherence to the Mediterranean diet. |
| Godos, 2017 [41] | MEAL, Italy | Cross-sectional | NA | 1936 | 976 | MF | ≥18 y | 110-item FFQ | Phenol-Explorer database | Phenolic acids (and subclasses and individual polyphenols) | Blood pressure measured during clinical visit | USDA database, Japan Functional Food Factor Database, Rural Development Administration Food Functional Composition Table |
| Yang, 2012 [42] | KNHANES, Korea | Cross-sectional | NA | 4745 | NR | MF | 20–69 y (range) | 24 h dietary recalls | Flavanols | Blood pressure measured during clinical visit | Age, BMI, education, current drinking, vitamin/mineral supplement use, functional food use, intakes of total energy, fat, fiber, and carbohydrate. |
| Richardson, 2016 [43] | CARDIA, USA | Cross-sectional | NA | 3142 | 843 | MF | 18–30 y (range) | 100-item FFQ | US Database | Isoflavones | Blood pressure measured during clinical visit | Age, sex, BMI, smoking, alcohol intake, physical activity, total energy, and sodium intake. |
### Table 1. Cont.

| Author, Year       | Cohort Name, Country | Study Design | Follow-Up (Years of Study) | Total Population (Analyzed Sample) | Cases (Hypertension/High Blood Pressure) | Sex | Age | Dietary Assessment | Polyphenol Estimation | Polyphenol Classes | Hypertension Assessment | Adjustments |
|--------------------|----------------------|--------------|-----------------------------|------------------------------------|----------------------------------------|-----|-----|-------------------|---------------------|---------------------|----------------------|--------------|
| Godos, 2018 [44]  | MEAL, Italy          | Cross-sectional | NA                          | 1936                               | 976                                    | MF  | ≥18 y | 110-item FFQ      | Phenol-Explorer database | Total phytoestrogens, isoflavones (and individual polyphenols), lignans (and individual polyphenols) | Blood pressure measured during clinical visit | Age, energy intake, smoking status, alcohol consumption, physical activity level, educational level, occupational level, sodium and potassium intake. Recruitment center, sex, age, smoking, soft drinks, carbohydrates, saturated fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids, n3 fatty acids, and dairies. Blood pressure at baseline, age, BMI, alcohol consumption, smoking status, physical activity, energy, energy-adjusted salt, saturated fats, green and yellow vegetables, pickled vegetables, fruits and fish, public health status, and menopausal status. Age, calcium intake, fiber intake, egg consumption in both men and women, soda drink consumption for isoflavones analysis in men and current smoking, higher education, regular exercise, and total energy intake for soy protein/isoflavones analyses in men. |
| Creus-Cuadros, 2017 [45] | PREDIMED, Spain | Cross-sectional | NA                          | 7169                               | NR                                     | MF  | ~67 y (mean) | 137-item FFQ | Phenol-Explorer database | Lignans       | Blood pressure measured during clinical visit | |
| Nozue, 2017 [46]  | JPHC II, Japan       | Prospective   | 5 y (1993–NR)               | 4165                               | 1335                                   | MF  | 40–69 y (range) | 52-item FFQ | Published literature | Isoflavones | Blood pressure measured during clinical visit | |
| Woo, 2018 [47]    | MRCohort, South Korea | Prospective   | 3.6 y (median, 2005–2013)   | 5509                               | NR                                     | MF  | ≥40 y | 106-item FFQ | USDA database         | Isoflavones       | Blood pressure measured during clinical visit | Age, BMI, use of hormone replacement therapy, smoking, dietary fiber intake, and potassium intake. |
| de Kleijn, 2002 [48] | Framingham Offspring Study, USA | Cross-sectional | NA                          | 939                                | F                                      | F   | 59 ± 7.5 y (mean) | 130-item FFQ | Published literature | Isoflavones, lignans | Blood pressure measured during clinical visit | |
| Author, Year | Cohort Name, Country | Study Design | Follow-Up (Years of Study) | Total Population (Analyzed Sample) | Cases (Hypertension/High Blood Pressure) | Sex | Age | Dietary Assessment | Polyphenol Estimation | Polyphenol Classes | Hypertension Assessment | Adjustments |
|--------------|----------------------|--------------|---------------------------|-------------------------------------|----------------------------------------|-----|-----|-------------------|---------------------|------------------|---------------------|-------------|
| Kreijkamp-Kaspers, 2004 [49] | Prospect-EPIC, The Netherlands | Cross-sectional | NA | 301 | 113 | F | 60–75 y (range) | FFQ | Published literature | Isoflavones, lignans | Blood pressure measured during clinical visit | Age, cholesterol lowering medication, use of antihypertensives, BMI, waist/hip ratio, smoking, physical activity, total energy intake, alcohol intake, saturated fat, monounsaturated fat, polyunsaturated fat, time postmenopausal, fiber intake, fruit intake, vegetable intake, and vitamin C intake. |
| Witkowska, 2018 [50] | WOBASZ and WOBASZ II, Poland | Cross-sectional | NA | 2599 | 1635 | F | ≥20 y | 24 h dietary recalls | Published literature | Lignans (and individual polyphenols) | Blood pressure measured during clinical visit | Age, smoking, BMI, alcohol intake, education, leisure-time physical activity, glucose level, cholesterol level, menopause hormone therapy, energy intake. |

Abbreviations: CARDIA (Coronary Artery Risk Development in Young Adults); E3N (Etude Epidémiologique auprès des femmes de la Mutuelle Générale de l’Education Nationale); EPIC (European Prospective Study into Nutrition and Cancer); F (Female); FFQ (Food Frequency Questionnaire); HAPIEE (Health, Alcohol, and Psychosocial factors In Eastern Europe); HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence); HPFS (Health Professionals Follow-Up Study); JPHC II (Japan Public Health Center–Based Cohort II); KNHANES (Korean National Health and Nutrition Examination Survey); M (Male); MEAL (Mediterranean healthy Eating, Ageing, and Lifestyle); MRCohort (Multi-Rural Communities Cohort); NA (Not applicable); NHS I (Nurses’ Health Study I); NHS II (Nurses’ Health Study II); NR (Not Reported); PA (physical activity); PREDIMED (Prevención con Dieta Mediterránea); TGLS (Tehran Lipid and Glucose Study); USDA (US Department of Agriculture).
Several studies have been conducted investigating individual classes or single compounds. A study from the same Brazilian cohort focused the analysis on “coffee polyphenols”, mostly including phenolic acids: the study showed a significant inverse associations between moderate intake of phenolic acids (101–337 mg/d) and hypertension [40]. Another study focusing on the relation between phenolic acids and hypertension was conducted on a sample of southern Italian adults (the MEAL cohort, n = 1937; age 18–92) in which polyphenol intake was assessed by a validated FFQ and calculated through the Phenol-Explorer database; individuals in the highest quartile of phenolic acid intake (median intake = 522.2 mg/day) were less likely to have hypertension, while when considering individual subclasses of phenolic acids, only hydroxyphenylacetic acids were inversely associated with hypertension [41]. Among the studies focusing the attention on one single class (or subclass) of polyphenols, an investigation conducted on 1827 men and 2918 women aged 20–69 years living in Korea (the KNHANES survey) calculated the intake of flavanols from 24-h dietary recalls using various databases on polyphenol content in foods (including the USDA Flavonoid Content of Food Database, the Japan Functional Food Factor Database, and the Rural Development Administration Food Functional Composition Table) reporting an inverse association with high blood pressure (defined as systolic blood pressure ≥130 mmHg and diastolic blood pressure ≥85 mmHg) in women but not in men [42].

3.3. Phytoestrogens and Blood Pressure/Hypertension

A total of eight studies investigated the association between total or individual phytoestrogen intake and blood pressure or occurrence of hypertension. A study recruiting African American and Caucasian men and women aged 18 to 30 years at baseline and following them up to 20 years; the authors reported that in multivariate adjusted models, the highest quartile of dietary isoflavone intake was associated with a 4.4 mm Hg lower SBP when compared with SBP for the lowest quartile [43]. Among studies conducted in individuals living in the Mediterranean area, participants of the MEAL cohort in the highest quartile of total phytoestrogens intake were less likely to be hypertensive, while no significant results were found for isoflavones and lignans separately; however, some individual compounds, such as biochanin A and pinoresinol showed an independent inverse association with hypertension [44]. Another study conducted in elderly individuals living in the Mediterranean area included participants of the PREDIMED trial, which showed no relation between lignan intake (estimated by Phenol-Explorer database) and blood pressure, while a significant inverse association was found when considering lignan intake together with low-fat dairy products [45]. Among studies conducted in Asian countries, where the major sources of phytoestrogens are soy products, participants of the JPHC-II (926 men and 3239 women) were examined through a FFQ including questions on soy consumption and isoflavone intake estimated with the use of Standard Tables of Food Composition in Japan, and development of high blood pressure, defined as systolic blood pressure >130 mm Hg or diastolic blood pressure >85 mm Hg or antihypertensive medication use; the study showed that isoflavones from total soy products was associated with lower risk of high blood pressure in women but not in men, while isoflavones from fermented soy product was associated in men but not in women [46]. Another study conducted on Korean men and women (n = 5509) aged more than 40 years old testing the association between soy isoflavones (calculated based on a database for foods consumed by Koreans and the USDA database) and high blood pressure (>130/85 mmHg) showed an inverse relation in both men and women, despite a linear association being observed only in women but not in men [47].

Given the weak estrogenic effects of phytoestrogens, some studies have been conducted focusing on post-menopausal women, which may sensibly benefit of such effect. A study conducted on 939 postmenopausal women participating in the Framingham Offspring Study aimed to assess the relation between phytoestrogen intake (assessed through self-administered FFQ and calculated by literature review) and cardiovascular risk factors, showed no significant differences between mean systolic and diastolic blood pressure across quartiles of isoflavones and lignans intake [48]. In another study conducted on 301 postmenopausal women (aged 60–75 years) living in The Netherlands exploring dietary phytoestrogen intake assessed using a FFQ covering the year prior to enrolment, no associations
were found for higher intake of isoflavones and systolic and diastolic blood pressures, while it was observed lower systolic and diastolic blood pressures and a lower prevalence of hypertension associated with higher lignans intake [49]. Finally, a study conducted on post-menopausal Polish women participating to the WOBASZ and WOBASZ II surveys (n = 2599) assessing dietary lignans intake using a single 24-h recall and the Dutch lignan database (together with other various sources derived from the literature) reported no relation of total and individual lignans and having hypertension [50].

3.4. Quantitative Meta-Analysis for Dietary Flavonoid Intake and Risk of Hypertension

Comparable data to perform meta-analysis of risk estimates was available only for prospective studies exploring the relation between dietary flavonoid (including all subclasses of flavonoids) intake and risk of hypertension. Forest plots comparing the highest versus the lowest intake of flavonoid intake (total and subclasses) and risk of hypertension are shown in Figure 2.

| Study or Subgroup | log(Odds Ratio) | SE | Weight | Risk Ratio, 95% CI | Risk Ratio, 95% CI |
|-------------------|----------------|----|--------|-------------------|-------------------|
| Total flavonoids  |                |    |        |                   |                   |
| Cassidy 2011 (HPS) | 0.0583         | 0.0453 | 20.3%  | 1.06 [0.97, 1.16] |                   |
| Cassidy 2011 (HNS) | -0.0619        | 0.0231 | 26.9%  | 0.94 [0.90, 0.98] |                   |
| Cassidy 2011 (HNS II) | 0.01 | 0.0312 | 24.4%  | 1.01 [0.95, 1.07] |                   |
| Lagus 2016 (Women) | -0.1278        | 0.0298 | 24.8%  | 0.88 [0.83, 0.93] |                   |
| Grosso 2017 (Men)  | 0.01           | 0.0219 | 1.3%   | 1.01 [0.97, 1.17] |                   |
| Grosso 2017 (Women)| -0.4643        | 0.2988 | 2.1%   | 0.64 [0.40, 1.02] |                   |

**Total (95% CI):** 1.00.0% 0.96 [0.89, 1.03]

**Heterogeneity:** Tau² = 0.00; Chi² = 19.29; df = 5 (P = 0.002); I² = 74%

**Test for overall effect:** Z = 1.20 (P = 0.23)

| Flavonols |                |    |        |                   |                   |
|-----------|----------------|----|--------|-------------------|-------------------|
| Cassidy 2011 (HPS) | 0.0677         | 0.0501 | 20.2%  | 1.07 [0.97, 1.18] |                   |
| Cassidy 2011 (HNS II) | -0.0408       | 0.0373 | 25.6%  | 0.96 [0.91, 1.01] |                   |
| Cassidy 2011 (HNS II) | 0.0116        | 0.0166 | 24.6%  | 1.00 [0.94, 1.06] |                   |
| Grosso 2017 (Men)  | 0.3416         | 0.2958 | 1.8%   | 1.41 [0.79, 2.52] |                   |
| Grosso 2017 (Women) | 0.3177         | 0.2626 | 2.8%   | 1.43 [0.96, 2.17] |                   |
| Lagus 2016 (Women) | -0.1393        | 0.0302 | 25.0%  | 0.87 [0.82, 0.92] |                   |

**Total (95% CI):** 1.00.0% 0.98 [0.91, 1.07]

**Heterogeneity:** Tau² = 0.01; Chi² = 23.49; df = 5 (P = 0.0007); I² = 77%

**Test for overall effect:** Z = 0.37 (P = 0.71)

| Flavonones |                |    |        |                   |                   |
|------------|----------------|----|--------|-------------------|-------------------|
| Cassidy 2011 (HPS) | 0.0862         | 0.0541 | 17.4%  | 1.09 [0.98, 1.21] |                   |
| Cassidy 2011 (HNS II) | -0.005        | 0.0271 | 29.1%  | 0.97 [0.92, 1.02] |                   |
| Cassidy 2011 (HNS II) | -0.0151       | 0.0191 | 23.4%  | 0.95 [0.88, 1.03] |                   |
| Lagus 2016 (Women) | -0.1054        | 0.0292 | 28.3%  | 0.96 [0.95, 0.99] |                   |
| Grosso 2017 (Men)  | -0.0384        | 0.0314 | 0.9%   | 0.92 [0.89, 1.07] |                   |
| Grosso 2017 (Women) | -0.3425        | 0.2928 | 1.1%   | 0.71 [0.40, 1.26] |                   |

**Total (95% CI):** 1.00.0% 0.96 [0.90, 1.02]

**Heterogeneity:** Tau² = 0.00; Chi² = 11.42; df = 5 (P = 0.04); I² = 56%

**Test for overall effect:** Z = 1.29 (P = 0.20)

| Flower 5-sht |                |    |        |                   |                   |
|--------------|----------------|----|--------|-------------------|-------------------|
| Cassidy 2011 (HPS) | 0.1133         | 0.0477 | 20.5%  | 1.12 [1.02, 1.23] |                   |
| Cassidy 2011 (HNS II) | -0.0020       | 0.0267 | 28.0%  | 0.98 [0.91, 1.03] |                   |
| Cassidy 2011 (HNS II) | 0.0202        | 0.0306 | 25.3%  | 1.03 [0.97, 1.09] |                   |
| Lagus 2016 (Women) | -0.0723        | 0.0344 | 24.2%  | 0.93 [0.87, 0.99] |                   |
| Grosso 2017 (Men)  | -0.2107        | 0.2887 | 1.7%   | 0.81 [0.46, 1.45] |                   |
| Grosso 2017 (Women) | -0.5978        | 2.1967 | 2.6%   | 0.55 [0.35, 0.86] |                   |

**Total (95% CI):** 1.00.0% 0.98 [0.92, 1.04]

**Heterogeneity:** Tau² = 0.00; Chi² = 12.81; df = 5 (P = 0.03); I² = 65%

**Test for overall effect:** Z = 0.74 (P = 0.46)

| Anthocyanins |                |    |        |                   |                   |
|--------------|----------------|----|--------|-------------------|-------------------|
| Cassidy 2011 (HPS) | -0.0101        | 0.0486 | 17.6%  | 0.99 [0.96, 1.02] |                   |
| Cassidy 2011 (HNS II) | -0.0762       | 0.0258 | 30.5%  | 0.94 [0.84, 0.98] |                   |
| Cassidy 2011 (HNS II) | -0.1393        | 0.0160 | 24.3%  | 0.87 [0.83, 0.93] |                   |
| Lagus 2016 (Women) | -0.1054        | 0.0532 | 25.2%  | 0.90 [0.84, 0.96] |                   |
| Grosso 2017 (Men)  | -0.0819        | 0.2731 | 0.8%   | 0.94 [0.91, 1.04] |                   |
| Grosso 2017 (Women) | 0.27           | 0.2033 | 1.5%   | 1.14 [0.84, 1.55] |                   |

**Total (95% CI):** 1.00.0% 0.92 [0.68, 0.97]

**Heterogeneity:** Tau² = 0.00; Chi² = 8.18; df = 5 (P = 0.15); I² = 73%

**Test for overall effect:** Z = 3.16 (P = 0.002)

Figure 2. Forest plot of summary relative risks (RRs) of hypertension for the highest versus lowest (reference) category of dietary flavonoid intake.
The analysis showed a non-significant association with decreased risk of hypertension (RR: 0.96, 95% CI: 0.89, 1.03; Figure 2) with significant heterogeneity ($I^2 = 74\%$, $P_{\text{heterogeneity}} = 0.01$), but no evidence of publication bias (Supplementary Figure S1). Exclusion of one study at the time revealed that significant results could be retrieved when not considering the HPFS cohort, despite the exclusion not reducing heterogeneity between remaining studies. A sensitivity analysis of subgroups defined by variables that may be responsible for heterogeneity showed significant results when considering only women and studies conducted in Europe, while no further evidence was found when considering studies with larger samples and longer follow-up (Table 2).

Table 2. Subgroup analyses of studies reporting risk of hypertension for the highest versus lowest (reference) category of dietary flavonoids

| Subgroup/Additional Analysis | No. of Cohorts | RR (95% CI) | $I^2$ | $P_{\text{heterogeneity}}$ |
|-----------------------------|----------------|------------|------|-----------------------------|
| Total                       | 5              | 0.96 (0.89, 1.03) | 74%  | 0.002                       |
| Sex                         |                |            |      |                             |
| Male                        | 2              | 1.06 (0.97, 1.16) | 0%   | 0.87                        |
| Female                      | 4              | 0.93 (0.87, 1.00) | 76%  | 0.005                       |
| Geographical area           |                |            |      |                             |
| Europe                      | 2              | 0.88 (0.83, 0.93) | 0%   | 0.37                        |
| North America               | 3              | 0.99 (0.93, 1.07) | 73%  | 0.02                         |
| Number of cases             |                |            |      |                             |
| >10,000                     | 2              | 0.97 (0.91, 1.04) | 72%  | 0.06                        |
| <10,000                     | 3              | 0.93 (0.79, 1.10) | 79%  | 0.003                       |
| Follow-up                   |                |            |      |                             |
| >10y                        | 4              | 0.97 (0.90, 1.04) | 82%  | 0.0009                      |
| <10y                        | 1              | 0.78 (0.50, 1.21) | 31%  | 0.23                        |
| Adjusted for smoking        |                |            |      |                             |
| No                          | 0              | NA         | NA   | NA                          |
| Yes                         | 5              | 0.96 (0.89, 1.03) | 74%  | 0.002                       |
| Adjusted for potassium/sodium|            |            |      |                             |
| No                          | 0              | NA         | NA   | NA                          |
| Yes                         | 5              | 0.96 (0.89, 1.03) | 74%  | 0.002                       |
| Adjusted for physical activity|            |            |      |                             |
| No                          | 0              | NA         | NA   | NA                          |
| Yes                         | 5              | 0.96 (0.89, 1.03) | 74%  | 0.002                       |
| Adjusted for BMI            |                |            |      |                             |
| No                          | 0              | NA         | NA   | NA                          |
| Yes                         | 5              | 0.96 (0.89, 1.03) | 74%  | 0.002                       |
| Adjusted for education      |                |            |      |                             |
| No                          | 3              | 0.99 (0.93, 1.07) | 73%  | 0.02                        |
| Yes                         | 2              | 0.88 (0.83, 0.93) | 0%   | 0.37                        |

The analysis of individual flavonoid subclasses showed significant association with hypertension risk reduction for higher intake anthocyanins with no evidence of significant heterogeneity and no evidence of publication bias at funnel plot (Supplementary Figure S1) whereas no association for extreme categories of exposure of flavonols, flavones, flavanones, and flavan-3-ols, was found (Figure 2). Sensitivity analysis conducted by excluding one study at a time revealed that also flavones were significantly associated with decreased risk of hypertension after exclusion of the HPFS cohort (with no significant heterogeneity and no evidence of publication bias) while all other results remained stably not significant.
4. Discussion

In this systematic review and meta-analysis, we reviewed existing studies on dietary polyphenols and blood pressure in epidemiological studies and investigated the association between total or individual subclasses of flavonoid intake and risk of hypertension in prospective cohort studies. The epidemiological studies evaluating the association between total dietary polyphenols and cardio-metabolic risk factors, including hypertension, generally showed contrasting results. Among articles with cross-sectional design, while no study but one [38] reported an inverse association between total polyphenol or flavonoid intake and occurrence of hypertension, few studies reported significant results for phenolic acids [40,41]. The findings on the relation between dietary phytoestrogens intake and blood pressure are more univocal, with general significant inverse association between intake of either isoflavones or lignans and blood pressure levels, despite heterogeneity of results between sexes and the cross-sectional design of most of the studies reviewed limiting the level of evidence. Among subclasses of flavonoids, the meta-analysis showed that dietary intake of anthocyanins was significantly associated with reduced risk of hypertension: comparison of the highest vs. lowest anthocyanins exposure showed an 8% reduction in risk of hypertension. Moreover, after exclusion of data from one cohort, also the analyses for total flavonoids and flavones demonstrated significant results. Significant heterogeneity between studies observed for total flavonoids should be considered as a major limitation of these findings. Nevertheless, heterogeneity was mainly related to the strength of the association rather than to the direction of risk estimates, suggesting overall promising perspectives for future studies.

Existing literature on studies aiming to explore the relation between flavonoid-rich foods, dietary flavonoids and hypertension is generally consistent but not univocal. Two meta-analyses of dietary interventions characterized by isocaloric diets with pulses or fruits and vegetables (including one portion of berries/day and 50 g of dark chocolate) showed significant reduction in systolic/diastolic blood pressure [51] and of markers of endothelial function [52], respectively. Among major food sources of anthocyanins, potential blood pressure lowering effects have been demonstrated for pomegranate juice [53] and berries [54,55], whereas a lack of effects has been reported for blueberry supplementation [56]. Among food sources of isoflavones, a meta-analysis exploring the effects of soybeans on blood pressure in postmenopausal women showed that ingestion of ≥25 g soy protein per day had blood pressure-lowering effects, and the improvements in blood pressure may be due to the isoflavones component of soy protein [57]. Other sources of phytoestrogens are seeds, which are rich in lignans: meta-analyses on clinical trials evaluating the effects of flaxseeds and sesame consumption on blood pressure concluded that they both may exert blood pressure-lowering effects [58,59]. Among the major sources of phenolic acids, the most comprehensive meta-analysis of cohort studies on coffee consumption and incidence of new-onset hypertension reported a modest decrease in risk of hypertension [60], while several meta-analyses investigating the effects of tea on blood pressure, showing potential benefits for long-term (>12 weeks) intake [61,62] and significant effects also for secondary prevention of cardiovascular disease among overweight and obese adults [63] and in individuals within pre-hypertensive and hypertensive ranges [64]. However, meta-analysis of clinical trials on polyphenol supplementation showed contrasting results. A previous meta-analysis of randomized controlled trials on the effects of anthocyanins on blood pressure showed overall null results [65]. Other meta-analyses on soy isoflavones supplementation reported that soy isoflavone extracts significantly decreased systolic but not diastolic blood pressure in adult humans, and no dose–response relationship was observed [66], while another meta-analysis suggested that the effects were more evident in hypertensive, but not in normotensive individuals [67]. Similarly, the beneficial potential of flaxseed to reduce blood pressure may be greater when it is consumed as a whole seed rather than as lignan extract [68]. Possible reasons for such scarce findings may depend on limitations in the study design of the trials included in the analysis, or on the short-term consumption to which the trials refer, which may be indicative of potential acute effects, but not equivalent to long term consumption. Moreover, supplementation using pharmaceutical formulas (i.e., pills or capsules) of
pure extracts may not be equivalent to dietary intake. Finally, it has been suggested that flavonoid bioactivity may not follow a classical linear dose–response association, and attention should be payed when designing and pooling together results from randomized controlled trials [69].

Flavonoids have been hypothesized to exert beneficial effects towards the cardiovascular system through their antioxidant and antiradical action, exerted through a variety of molecular mechanisms [70], and importantly, as demonstrated in both experimental and clinical studies, altered oxidative imbalance is linked to higher cardiovascular risk [71–74]. Furthermore, flavonoids may also act more specifically as signaling molecules, interacting with cellular receptors or proteins that are involved in regulatory pathways, resulting in physiological responses or regulation of gene expression [70]. Regarding their potential effects on endothelial function and regulation of vasodilatory processes associated with blood-flow, flavonoids can act as inhibitors of endothelial NAD(P)H oxidase, which has been linked to the regulation of nitric oxide (NO) levels in the vascular endothelium via inhibition of superoxide production [75]. Specific classes of phenolic compounds or their metabolites have been reported to improve endothelial dysfunction through their antioxidant attitude, but also directly acting over NO metabolism or reducing vasoconstriction by acting on ACE and angiotensin II receptor activity [76]. In particular, isoflavones have demonstrated interaction with the estrogen-response element of genes related to endothelial NO synthase leading to increase in endogenous NO production [77]. Furthermore, in several studies, flavonoids were shown to modulate inflammation through inflammatory cell infiltration, lowered levels of pro-inflammatory cytokines, and improved cell survival and function. These anti-inflammatory effects were mediated via inhibition of NF-κB [78,79]. Concerning anthocyanins, the only subclass of flavonoids that was significantly associated with decreased risk of hypertension in the present study, their effects involve targeting the NF-κB signaling pathway, activator protein 1(AP-1), the Phase II enzyme activation and Nrf2, and the mitogen-activated protein kinase (MAPK) signaling pathway [80]. Anthocyanins were shown to exert inhibitory action against vasodilators. In example, blackberry juice containing cyanidin-3-O-glucoside was shown to exert protective effects against endothelial dysfunction and vascular failure via scavenging of peroxynitrate, a strong oxidant responsible for DNA and protein damage [81]. In line with those results, another study demonstrated that anthocyanin fraction of blackberry extract was able to suppress NO production via inhibition of inducible NO synthase due to the attenuation of NK-κB and MAPK signaling pathways [82]. Cyanidin-3-O-glucoside was shown to regulate the phosphorylation of endothelial NO synthase, thus ameliorating endothelial dysfunction and regulating blood pressure [83,84]. Finally, delphinidin, an anthocyanin present in red wine, was demonstrated to inhibit endothelial cell apoptosis via NO pathway and regulation of calcium homeostasis [85]. However, when taking into account the results obtained for anthocyanins, it should be considered that anthocyanins are relatively unstable molecules, as they undergo re-arrangements in response to pH. Depending on the nature of compound and sugar conjugation, anthocyanins were shown to reach the human colon after ingestion [86]. Despite laboratory studies providing the biological rationale for the potential association of dietary flavonoids and, in particular, anthocyanins and risk of hypertension, the overall results need to be further clarified by additional experimental and epidemiological studies.

Some limitations of the included studies may explain the retrieved heterogeneity of results and the lack of significance of certain analyses. First, differences in polyphenol food content databases used among studies may lead to different ‘weighting’ of food items selected in terms of flavonoid content. Moreover, only some compounds are known to exert beneficial effects toward the endothelium [87], and intra- and inter-individual differences in absorption and metabolism of such compounds may enhance or reduce such activity. Secondly, food items included in dietary questionnaires comprised different numbers of foods containing flavonoids, thus further potentially biasing the real content of polyphenols. Additionally, studies with only baseline evaluation of food intake may not have taken into account possible changes of the diet over the follow-up period. However, as the exposure was ascertained before the diagnosis of hypertension, misclassification would tend to underestimate
the true associations. Moreover, the role of individual dietary compounds is difficult to disentangle, as intake of polyphenols has been reported to correlate with the intake of fruits and vegetables and their constituents—i.e., vitamin C, vitamin E, carotenoids, folate, and fiber—which may confound or act synergistically toward the risk of chronic diseases [88]. Finally, subgroup analyses showed significant results only among women. A possible explanation for this is the natural differences occurring between men and women due to hormonal protection in the latter before menopause. However, these potential differences need to be further investigated.

5. Conclusions

In conclusion, results from this study are promising but not conclusive. Further studies are needed to elucidate the retrieved association between polyphenol consumption and decreased risk of hypertension and to clarify whether individual subclasses, rather than the total content of polyphenols, may exert beneficial effects on blood pressure.

Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/8/6/152/s1, Figure S1: Funnel plot for hypertension risk of the highest versus lowest (reference) category of dietary flavonoid intake, Table S1: PRISMA checklist.

Author Contributions: J.G. and A.M. performed search and analysis; J.G. and M.V. drafted the paper (equal contribution); S.R., D.M., D.D.R., G.R., F.G., and G.G. drafted the paper and provided insights on the topic. All authors critically revised and approved final version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Del Rio, D.; Costa, L.G.; Lean, M.E.; Crozier, A. Polyphenols and health: What compounds are involved? Nutr. Metab. Cardiovasc. Dis. 2010, 20, 1–6. [CrossRef]
2. Grosso, G.; Godos, J.; Lamuela-Raventos, R.; Ray, S.; Micek, A.; Pajak, A.; Sciacca, S.; D’Orazio, N.; Del Rio, D.; Galvano, F. A comprehensive meta-analysis on dietary flavonoid and lignan intake and cancer risk: Level of evidence and limitations. Mol. Nutr. Food Res. 2017, 61. [CrossRef]
3. Grosso, G.; Micek, A.; Godos, J.; Pajak, A.; Sciacca, S.; Galvano, F.; Giovannucci, E.L. Dietary flavonoid and lignan intake and mortality in prospective cohort studies: Systematic review and dose-response meta-analysis. Am. J. Epidemiol. 2017, 12, 1304–1316. [CrossRef]
4. Del Rio, D.; Rodriguez-Mateos, A.; Spencer, J.P.; Tognolini, M.; Borges, G.; Crozier, A. Dietary (poly)phenolics in human health: Structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid. Redox Signal. 2013, 18, 1818–1892. [CrossRef]
5. Kumar, S.; Pandey, A.K. Chemistry and biological activities of flavonoids: An overview. Sci. World J. 2013, 2013, 162750. [CrossRef]
6. Grosso, G.; Stepaniak, U.; Topor-Madry, R.; Szafraniec, K.; Pajak, A. Estimated dietary intake and major food sources of polyphenols in the polish arm of the hapiee study. Nutrition 2014, 30, 1398–1403. [CrossRef]
7. Zamora-Ros, R.; Knaze, V.; Lujan-Barroso, L.; Romieu, I.; Scalbert, A.; Slimani, N.; Hjartaker, A.; Engeset, D.; Skeie, G.; Overvad, K.; et al. Differences in dietary intakes, food sources and determinants of total flavonoids between mediterranean and non-mediterranean countries participating in the european prospective investigation into cancer and nutrition (epic) study. Br. J. Nutr. 2013, 109, 1498–1507. [CrossRef]
8. Godos, J.; Marventano, S.; Mistretta, A.; Galvano, F.; Grosso, G. Dietary sources of polyphenols in the mediterranean healthy eating, aging and lifestyle (meal) study cohort. Int. J. Food Sci. Nutr. 2017, 68, 750–756. [CrossRef]
9. Perez-Jimenez, J.; Neveu, V.; Ves, F.; Scalbert, A. Identification of the 100 richest dietary sources of polyphenols: An application of the phenol-explorer database. Eur. J. Clin. Nutr. 2010, 64, S112–S120. [CrossRef]
10. Tresserra-Rimbau, A.; Medina-Remon, A.; Perez-Jimenez, J.; Martinez-Gonzalez, M.A.; Covas, M.I.; Corella, D.; Salas-Salvado, J.; Gomez-Gracia, E.; Lapetra, J.; Aros, F.; et al. Dietary intake and major food sources of polyphenols in a spanish population at high cardiovascular risk: The predimed study. Nutr. Metab. Cardiovasc. Dis. 2013, 23, 953–959. [CrossRef]
11. Vitale, M.; Masulli, M.; Rivellese, A.A.; Bonora, E.; Cappellini, F.; Nicolucci, A.; Squatrito, S.; Antenucci, D.; Barrea, A.; Bianchi, C.; et al. Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The tosca.it study. Eur. J. Nutr. 2016. [CrossRef]

12. Angelino, D.; Godos, J.; Gelifi, F.; Tieri, M.; Titta, L.; Lafranconi, A.; Marventano, S.; Alonzo, E.; Gambera, A.; Sciaccia, S.; et al. Fruit and vegetable consumption and health outcomes: An umbrella review of observational studies. Int. J. Food Sci. Nutr. 2019, 1–16. [CrossRef]

13. Grosso, G.; Bella, F.; Godos, J.; Sciacca, S.; Del Rio, D.; Ray, S.; Galvano, F.; Giovannucci, E.L. Possible role of flavonoid intake and alternative healthy eating index dietary patterns and mortality from all causes, cardiovascular disease and cancer: A meta-analysis of observational studies. J. Hum. Nutr. Diet. 2017, 30, 216–226. [CrossRef]

14. Onvani, S.; Haghighatdoost, F.; Surkan, P.J.; Larijani, B.; Azadbakht, L. Adherence to the healthy eating index and neurotoxicity in Wistar rats. Pharm. Biol. 2017, 55, 1–7. [CrossRef]

15. Qian, Y.; Babu, P.V.A.; Symons, J.D.; Jalili, T. Metabolites of flavonoid compounds preserve indices of endothelial cell nitric oxide bioavailability under glucotoxic conditions. Nutr. Diabetes 2017, 7, e286. [CrossRef]
29. Medina-Remon, A; Zamora-Ros, R; Rotches-Ribalta, M; Andres-Lacueva, C; Martinez-Gonzalez, M.A.; Covas, M.I.; Corella, D; Salas-Salvado, J; Gomez-Gracia, E; Ruiz-Gutierrez, V; et al. Total polyphenol excretion and blood pressure in subjects at high cardiovascular risk. *Nutr. Metab. Cardiovasc. Dis*. 2011, 21, 323–331. [CrossRef]

30. Medina-Remon, A; Tresserra-Rimbau, A; Pons, A; Tur, J.A.; Martorell, M; Ros, E; Buil-Cosiales, P; Sacanella, E; Covas, M.I.; Corella, D; et al. Effects of total dietary polyphenols on plasma nitric oxide and blood pressure in a high cardiovascular risk cohort. The predimed randomized trial. *Nutr. Metab. Cardiovasc. Dis*. 2015, 25, 60–67. [CrossRef]

31. Wells, G.A; Shea, B; O’Connell, D; Peterson, J; Welch, V; Losos, M; Tugwell, P. *The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses*; Ottawa Health Research Institute: Ottawa, ON, Canada, 1999.

32. Cassidy, A; O’Reilly, E.J; Kay, C; Sampson, L; Franz, M; Forman, J.P; Curhan, G; Rimm, E.B. Habitual intake of flavonoid subclasses and incident hypertension in adults. *Am. J. Clin. Nutr*. 2011, 93, 338–347. [CrossRef]

33. Grosso, G; Stepaniak, U; Micek, A; Kozela, M; Stefler, D; Bobak, M; Pajak, A. Dietary polyphenol intake and risk of hypertension in the polish arm of the hapiee study. *Eur. J. Nutr*. 2017, 4, 1535–1544. [CrossRef]

34. Lajous, M; Rossignol, E; Fagherazzi, G; Perquier, F; Scalbert, A; Clavel-Chapelon, F; Boutron-Ruault, M.C. Flavonoid intake and incident hypertension in women. *Am. J. Clin. Nutr*. 2016, 103, 1091–1098. [CrossRef]

35. Jennings, A; Welch, A.A; Fairweather-Tait, S.J; Kay, C; Minihane, A.M; Chowienczyk, P; Jiang, B; Cecelja, M; Spector, T; Macgregor, A; et al. Higher anthocyanin intake is associated with lower arterial stiffness and central blood pressure in women. *Am. J. Clin. Nutr*. 2012, 96, 781–788. [CrossRef]

36. Wisnuswardani, R.W; De Henauw, S; Forsnér, M; Gottrand, F; Huybrechts, I; Knaze, V; Kersting, M; Donne, C.L; Manios, Y; Marcos, A; et al. Polyphenol intake and metabolic syndrome risk in European adolescents: The HELENA study. *Eur. J. Nutr*. 2019. [CrossRef]

37. Grosso, G; Stepaniak, U; Micek, A; Stefler, D; Bobak, M; Pajak, A. Dietary polyphenols are inversely associated with metabolic syndrome in Polish adults of the HAPIEE study. *Eur. J. Nutr*. 2016, 4, 1409–1420. [CrossRef]

38. Sohrab, G; Hosseinpour-Niazi, S; Hejazi, J; Yuzbashian, E; Mirmiran, P; Azizi, F. Dietary polyphenols and metabolic syndrome among iranian adults. *Int. J. Food Sci. Nutr*. 2013, 64, 661–667. [CrossRef]

39. Miranda, A.M; Steluti, J; Fisberg, R.M; Marchioni, D.M. Association between polyphenol intake and hypertension in adults and older adults: A population-based study in Brazil. *PLoS ONE* 2016, 11, e0165791. [CrossRef]

40. Miranda, A.M; Steluti, J; Fisberg, R.M; Marchioni, D.M. Association between coffee consumption and its polyphenols with cardiovascular risk factors: A population-based study. *Nutrients* 2017, 9, 276. [CrossRef]

41. Godos, J; Sinatra, D; Blanco, I; Mule, S; La Verde, M; Marranzano, M. Association between dietary phenolic acids and hypertension in a Mediterranean cohort. *Nutrients* 2017, 9.

42. Yang, Y.J; Kim, Y.J; Yang, Y.K; Kim, J.Y; Kwon, O. Dietary flavan-3-ols intake and metabolic syndrome risk in Korean adults. *Nutr. Res. Pract*. 2012, 6, 68–77. [CrossRef] [PubMed]

43. Richardson, S.I; Steffen, L.M; Swett, K; Smith, C; Burke, L; Zhou, X; Shikany, J.M; Rodriguez, C.J. Dietary total isoflavone intake is associated with lower systolic blood pressure: The Coronary Artery Risk Development in Young Adults (CARDIA) study. *J. Clin. Hypertens*. 2016, 18, 778–783. [CrossRef] [PubMed]

44. Godos, J; Bergante, S; Satriano, A; Pluchinotta, F.R; Marranzano, M. Dietary phytoestrogen intake is inversely associated with hypertension in a cohort of adults living in the Mediterranean area. *Molecules* 2018, 23, 368. [CrossRef] [PubMed]

45. Creus-Cuadros, A; Tresserra-Rimbau, A; Quifer-Rada, P; Martinez-Gonzalez, M.A; Corella, D; Salas-Salvado, J; Fito, M; Estruch, R; Gomez-Gracia, E; Lapetra, J; et al. Associations between both lignan and yogurt consumption and cardiovascular risk parameters in an elderly population: Observations from a cross-sectional approach in the PREDIMED study. *J. Acad. Nutr. Diet*. 2017, 117, 609–622 e601. [CrossRef]

46. Nozue, M; Shimazu, T; Sasazuki, S; Charvat, H; Mori, N; Mutoh, M; Sawada, N; Iwasaki, M; Yamaji, T; Inoue, M; et al. Fermented soy product intake is inversely associated with the development of high blood pressure: The Japan public health center-based prospective study. *J. Nutr*. 2017, 147, 1749–1756. [CrossRef]

47. Woo, H.W; Kim, M.K; Lee, Y.H; Shin, D.H; Shin, M.H; Choi, B.Y. Habitual consumption of soy protein and isoflavones and risk of metabolic syndrome in adults ≥ 40 years old: A prospective analysis of the Korean multi-rural communities cohort study (MRCOHORT). *Eur. J. Nutr*. 2018. [CrossRef]
48. De Kleijn, M.J.; van der Schouw, Y.T.; Wilson, P.W.; Grobbee, D.E.; Jacques, P.F. Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U.S. women: The Framingham study. *J. Nutr.* 2002, 132, 276–282. [CrossRef]

49. Kreijkamp-Kaspers, S.; Kok, L.; Bots, M.L.; Grobbee, D.E.; van der Schouw, Y.T. Dietary phytoestrogens and vascular function in postmenopausal women: A cross-sectional study. *J. Hypertens.* 2004, 22, 1381–1388. [CrossRef]

50. Witkowska, A.M.; Waskiewicz, A.; Zujko, M.E.; Szczesniakowska, D.; Stepaniak, U.; Pajak, A.; Drygas, W. Are total and individual dietary lignans related to cardiovascular disease and its risk factors in postmenopausal women? A nationwide study. *Nutrients* 2018, 10, 865. [CrossRef]

51. Jayalath, V.H.; de Souza, R.J.; Sievenpiper, J.L.; Ha, V.; Chiavaroli, L.; Mirrahimi, A.; Di Buono, M.; Bernstein, A.M.; Leiter, L.A.; Kris-Etherton, P.M.; et al. Effect of dietary pulses on blood pressure: A systematic review and meta-analysis of controlled trials. *Am. J. Hypertens.* 2014, 27, 56–64. [CrossRef]

52. Noad, R.L.; Rooney, C.; McCall, D.; Young, I.S.; McCance, D.; McKinley, M.C.; Woodside, J.V.; McKeown, P.P. Beneficial effect of a polyphenol-rich diet on cardiovascular risk: A randomised control trial. *Heart* 2016, 102, 1371–1379. [CrossRef]

53. Sahebkar, A.; Ferri, C.; Giorgini, P.; Bo, S.; Nachtigal, P.; Grassi, D. Effect of sesame consumption improve blood pressure: A meta-analysis of randomised controlled trials. *Pharmacol. Res.* 2017, 115, 149–161. [CrossRef]

54. Huang, H.; Chen, G.; Liao, D.; Zhu, Y.; Xue, X. Effect of berries consumption on cardiovascular risk factors: A meta-analysis with trial sequential analysis of randomized controlled trials. *Sci. Rep.* 2016, 6, 23625. [CrossRef]

55. Kent, K.; Charlton, K.E.; Jenner, A.; Roodenrys, S. Acute reduction in blood pressure following consumption of anthocyanin-rich cherry juice may be dose-interval dependant: A pilot cross-over study. *Int. J. Food. Sci. Nutr.* 2016, 67, 47–52. [CrossRef]

56. Zhu, Y.; Sun, J.; Lu, W.; Wang, X.; Wang, X.; Han, Z.; Qiu, C. Effect of blueberry supplementation on blood pressure: A systematic review and meta-analysis of randomized clinical trials. *J. Hum. Hypertens.* 2017, 31, 165–171. [CrossRef]

57. Kou, T.; Wang, Q.; Cai, J.; Song, J.; Du, B.; Zhao, K.; Ma, Y.; Geng, B.; Zhang, Y.; Han, X.; et al. Effect of soybean protein on blood pressure in postmenopausal women: A meta-analysis of randomized controlled trials. *Food Funct.* 2017, 8, 2663–2671. [CrossRef]

58. Khosravi-Boroujeni, H.; Nikbakht, E.; Natanelov, E.; Khalesi, S. Can sesame consumption improve blood pressure? A systematic review and meta-analysis of controlled trials. *J. Sci. Food Agric.* 2017, 97, 3087–3094. [CrossRef]

59. Ursoniu, S.; Sahebkar, A.; Andrica, F.; Serban, C.; Banach, M.; Lipid and Blood Pressure Meta-analysis Collaboration. Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial. *Clin. Nutr.* 2016, 35, 615–625. [CrossRef]

60. Grosso, G.; Micek, A.; Godos, J.; Pajak, A.; Sciacca, S.; Bes-Rastrollo, M.; Galvano, F.; Martinez-Gonzalez, M.A. Long-term coffee consumption is associated with decreased incidence of new-onset hypertension: A dose-response meta-analysis. *Nutrients* 2017, 9, 890. [CrossRef]

61. Liu, G.; Mi, X.N.; Zheng, X.X.; Xu, Y.L.; Lu, J.; Huang, X.H. Effects of tea intake on blood pressure: A meta-analysis of randomised controlled trials. *Br. J. Nutr.* 2014, 112, 1043–1054. [CrossRef]

62. Serban, C.; Sahebkar, A.; Ursoniu, S.; Andrica, F.; Banach, M. Effect of sour tea (*Hibiscus sabdariffa L.*) on arterial hypertension: A systematic review and meta-analysis of randomized controlled trials. *J. Hypertens.* 2015, 33, 1119–1127. [CrossRef]

63. Liu, J.; Tang, W.; Sang, L.; Dai, X.; Wei, D.; Luo, Y.; Zhang, J. Milk, yogurt, and lactose intake and cancer risk: A meta-analysis. *Nutr. Cancer* 2015, 67, 68–72. [CrossRef]

64. Yarmolinsky, J.; Gon, G.; Edwards, P. Effect of tea on blood pressure for secondary prevention of cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. *Nutr. Rev.* 2015, 73, 236–246. [CrossRef]

65. Zhu, Y.; Bo, Y.; Wang, X.; Lu, W.; Wang, X.; Han, Z.; Qiu, C. The effect of anthocyanins on blood pressure: A prisma-compliant meta-analysis of randomized clinical trials. *Medicine* 2016, 95, e3880. [CrossRef]
66. Taku, K.; Lin, N.; Cai, D.; Hu, J.; Zhao, X.; Zhang, Y.; Wang, P.; Melby, M.K.; Hooper, L.; Kurzer, M.S.; et al. Effects of soy isoflavone extract supplements on blood pressure in adult humans: Systematic review and meta-analysis of randomized placebo-controlled trials. *J. Hypertens.* 2010, 28, 1971–1982. [CrossRef]
67. Liu, X.X.; Li, S.H.; Chen, J.Z.; Sun, K.; Wang, X.J.; Wang, X.G.; Hui, R.T. Effect of soy isoflavones on blood pressure: A meta-analysis of randomized controlled trials. *Nutr. Metab. Cardiovasc. Dis.* 2012, 22, 463–470. [CrossRef]
68. Khalesi, S.; Irwin, C.; Schubert, M. Flaxseed consumption may reduce blood pressure: A systematic review and meta-analysis of controlled trials. *J. Nutr.* 2015, 145, 758–765. [CrossRef]
69. Kay, C.D.; Hooper, L.; Kroon, P.A.; Rimm, E.B.; Cassidy, A. Relative impact of flavonoid composition, dose and structure on vascular function: A systematic review of randomised controlled trials of flavonoid-rich food products. *Mol. Nutr. Food Res.* 2012, 56, 1605–1616. [CrossRef]
70. Mena, P.; Dominguez-Perles, R.; Girones-Vilaplana, A.; Baenas, N.; Garcia-Viguera, C.; Villano, D. Flavan-3-ols, anthocyanins, and inflammation. *IUBMB Life* 2014, 66, 745–758. [CrossRef]
71. Ahmad, A.; Singhal, U.; Hossain, M.M.; Islam, N.; Rizvi, I. The role of the endogenous antioxidant enzymes and malondialdehyde in essential hypertension. *J. Clin. Diagn. Res.* 2013, 7, 987–990. [CrossRef]
72. Brunelli, E.; La Russa, D.; Pellegrino, D. Impaired oxidative status is strongly associated with cardiovascular risk factors. *Oxid. Med. Cell. Longev.* 2017, 2017, 6480145. [CrossRef]
73. La Russa, D.; Brunelli, E.; Pellegrino, D. Oxidative imbalance and kidney damage in spontaneously hypertensive rats: Activation of extrinsic apoptotic pathways. *Clin. Sci. (Lond.)* 2017, 131, 1419–1428. [CrossRef]
74. Ward, N.C.; Hodgson, J.M.; Puddey, I.B.; Mori, T.A.; Beilin, L.J.; Croft, K.D. Oxidative stress in human hypertension: Association with antihypertensive treatment, gender, nutrition, and lifestyle. *Free Radic. Biol. Med.* 2004, 36, 226–232. [CrossRef]
75. Hugel, H.M.; Jackson, N.; May, B.; Zhang, A.L.; Xue, C.C. Polyphenol protection and treatment of hypertension. *Phytomedicine* 2016, 23, 220–231. [CrossRef]
76. Clark, J.L.; Zahradka, P.; Taylor, C.G. Efficacy of flavonoids in the management of high blood pressure. *Nutr. Rev.* 2015, 73, 799–822. [CrossRef]
77. Ramdath, D.D.; Padhi, E.M.; Sarfaraz, S.; Renwick, S.; Duncan, A.M. Beyond the cholesterol-lowering effect of soy protein: A review of the effects of dietary soy and its constituents on risk factors for cardiovascular disease. *Nutrients* 2017, 9, 324. [CrossRef]
78. Rani, N.; Bharti, S.; Bhatia, J.; Nag, T.C.; Ray, R.; Arya, D.S. Chrysin, a ppar-gamma agonist improves myocardial injury in diabetic rats through inhibiting age-raged mediated oxidative stress and inflammation. *Chem. Biol. Interact.* 2016, 250, 59–67. [CrossRef]
79. Yuan, X.; Niu, H.T.; Wang, P.L.; Lu, J.; Zhao, H.; Liu, S.H.; Zheng, Q.S.; Li, C.G. Cardioprotective effects of licorice and metformin against myocardial ischemia/reperfusion injury in langendorff-perfused rat hearts. *PLoS ONE* 2015, 10, e0128375. [CrossRef]
80. De Pascual-Teresa, S.; Moreno, D.A.; Garcia-Viguera, C. Flavanols and anthocyanins in cardiovascular health: A review of current evidence. *Int. J. Mol. Sci.* 2010, 11, 1679–1703. [CrossRef]
81. Serraino, I.; Dugo, L.; Dugo, P.; Mondello, L.; Mazzon, E.; Dugo, G.; Caputi, A.P.; Cuzzocrea, S. Protective effects of cyanidin-3-O-glucoside from blackberry extract against peroxynitrite-induced endothelial dysfunction and vascular failure. *Life Sci.* 2003, 73, 1097–1114. [CrossRef]
82. Pergola, C.; Rossi, A.; Dugo, P.; Cuzzocrea, S.; Sautebin, L. Inhibition of nitric oxide biosynthesis by anthocyanin fraction of blackberry extract. *Nitric Oxide* 2006, 15, 30–39. [CrossRef]
83. Xun, Y.H.; Guo, J.C.; Lou, G.Q.; Jiang, Y.M.; Zhuang, Z.J.; Zhu, M.F.; Luo, Y.; Ma, X.J.; Liu, J.; Bian, D.X.; et al. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with nafl. *Clin. Exp. Pharmacol. Physiol.* 2014, 41, 643–649.
84. Xu, J.W.; Ikeda, K.; Yamori, Y. Upregulation of endothelial nitric oxide synthase by cyanidin-3-glucoside, a typical anthocyanin pigment. *Hypertension* 2004, 44, 217–222. [CrossRef]
85. Martin, S.; Giannone, G.; Andriantsitohaina, R.; Martinez, M.C. Delphinidin, an active compound of red wine, inhibits endothelial cell apoptosis via nitric oxide pathway and regulation of calcium homeostasis. *Br. J. Pharmacol.* 2003, 139, 1095–1102. [CrossRef]
86. Kahle, K.; Kraus, M.; Scheppach, W.; Ackermann, M.; Ridder, F.; Richling, E. Studies on apple and blueberry fruit constituents: Do the polyphenols reach the colon after ingestion? *Mol. Nutr. Food Res.* 2006, 50, 418–423. [CrossRef]

87. Vitaglione, P.; Donnarumma, G.; Napolitano, A.; Galvano, F.; Gallo, A.; Scalfi, L.; Fogliano, V. Protocatechuic acid is the major human metabolite of cyanidin-glucosides. *J. Nutr.* 2007, 137, 2043–2048. [CrossRef]

88. Riboli, E.; Slimani, N.; Kaaks, R. Identifiability of food components for cancer chemoprevention. *IARC Sci. Publ.* 1996, 23–31.

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).